Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on 4D Molecular Therapeutics (NASDAQ:FDMT) in the last three months. Summarizing their recent ...
4 analysts have shared their evaluations of 4D Molecular Therapeutics (NASDAQ:FDMT) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results